{"id":581414,"date":"2024-05-13T00:00:00","date_gmt":"2024-05-13T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0001-2024-biopharma-alzheimers-disease-current-treatment-physician-insights-us-2024\/"},"modified":"2026-05-12T11:21:13","modified_gmt":"2026-05-12T11:21:13","slug":"cutrcg0001-2024-biopharma-alzheimers-disease-current-treatment-physician-insights-us-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0001-2024-biopharma-alzheimers-disease-current-treatment-physician-insights-us-2024\/","title":{"rendered":"Alzheimer&#8217;s Disease | Current Treatment: Physician Insights | US | 2024"},"content":{"rendered":"<p>Alzheimer\u2019s disease (AD) affects cognition and may bring a spectrum of neuropsychiatric symptoms (e.g., agitation, aggression, psychosis) that intensify as the disease advances. Important new treatments reached the market in 2023, joining an array of modestly effective and largely generic procognitive options (e.g., acetylcholinesterase inhibitors, memantine). Eisai \/ Biogen\u2019s Leqembi (lecanemab) is poised to unlock the as-yet unfulfilled potential of a disease-modifying therapy (DMT) for early AD, and Lundbeck \/ Otsuka\u2019s Rexulti (brexpiprazole) is the first drug approved for AD agitation. This report will provide developers of new and emerging DMTs and neuropsychiatric treatments for AD with valuable insights into the patient characteristics driving or constraining eligibility for novel options. It will also delve into the path to diagnosis and treatment initiation in AD, as well as neurologists\u2019 and PCPs\u2019 prescribing practices and rationale.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What percentage of AD patients suffer from comorbid behavioral conditions? What do neurologists prescribe to treat these symptoms?<\/li>\n<li>How has neurologists\u2019 and PCPs\u2019 prescribing changed in the past year? What changes are they anticipating in the coming year?<\/li>\n<li>How do PCPs and neurologists differ in their prescribing practices?<\/li>\n<li>What types of assessments are physicians completing at follow-up appointments after initiating Leqembi?<\/li>\n<li>Which biomarker tests are clinicians using, and how?<\/li>\n<li>What percentage of AD patients are on antipsychotics, and what is the patient share of individual therapies?<\/li>\n<li>What tools are physicians using to assess AD patients&#8217; cognitive function?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so\u00a0that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><strong>Markets covered: <\/strong>United States<\/p>\n<p><strong>Primary research: <\/strong>Survey of 70 U.S. neurologists and 30 U.S. PCPs<\/p>\n<p><strong>Key drugs covered: <\/strong>Leqembi, Rexulti, Adlarity, donepezil, galantamine, memantine, Namzaric, rivastigmine, atypical antipsychotics, antidepressants<\/p>\n<p><strong>Key companies: <\/strong>Eisai \/ Biogen, Otsuka \/ Lundbeck, Corium, AbbVie<\/p>\n<p><strong>Key insights provided: <\/strong><\/p>\n<ul>\n<li>Factors influencing disease management and treatment decisions.<\/li>\n<li>Drivers and constraints of treatment selection.<\/li>\n<li>Physician-reported treatment practices and brand-level patient shares.<\/li>\n<li>Rationale for changes in treatment approach.<\/li>\n<li>Physician insight on persistency and compliance.<\/li>\n<li>Physician-reported recent\/anticipated changes in brand usage or treatment approach.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-581414","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/581414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/581414\/revisions"}],"predecessor-version":[{"id":581455,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/581414\/revisions\/581455"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=581414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}